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Introduction. Abdominal pain is common and is associated with high disease burden and 
health care costs in pediatric acute recurrent and chronic pancreatitis (ARP/CP). Despite the 
strong central component of pain in ARP/CP and the efficacy of psychological therapies for 
other centralized pain syndromes, no studies have evaluated psychological pain interventions in 
children with ARP/CP. The current trial seeks to 1) evaluate the efficacy of a psychological pain 
intervention for pediatric ARP/CP, and 2) examine baseline patient-specific genetic, clinical, and 
psychosocial characteristics that may predict or moderate treatment response.  Methods. This 
single-blinded randomized placebo-controlled multicenter trial aims to enroll 260 youth (ages 
10-18) with ARP/CP and their parents from twenty-one INSPPIRE (INternational Study Group
of Pediatric Pancreatitis: In search for a cuRE) centers. Participants will be randomly assigned 
to either a web-based cognitive behavioral pain management intervention (Web-based 
Management of Adolescent Pain Chronic Pancreatitis; WebMAP; N = 130) or to a web-based 
pain education program (WebED; N = 130). Assessments will be completed at baseline (T1), 
immediately after completion of the intervention (T2) and at 6 months post-intervention (T3). 
The primary study outcome is abdominal pain severity. Secondary outcomes include pain-related 
disability, pain interference, health-related quality of life, emotional distress, impact of pain, 
opioid use, and healthcare utilization. Conclusions. This is the first clinical trial to evaluate the 
efficacy of a psychological pain intervention for children with CP for reduction of abdominal 
pain and improvement of health-related quality of life. Findings will inform delivery of web-
based pain management and potentially identify patient-specific biological and psychosocial 
factors associated with favorable response to therapy.  
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Abdominal pain occurs in ~80% of children with acute recurrent or chronic pancreatitis 
(ARP/CP) and is associated with increased disease burden and economic costs [1, 2]. As pain 
related to pancreatitis becomes more frequent and severe, it can lead to significant decline in 
children’s health and functioning, including frequent missed school days, emergency room visits 
and recurrent hospitalizations [3, 4], and greater exposure to opioids [5]. Moreover, pain 
associated with pediatric ARP/CP may continue into adulthood, often with worsening disease 
and reduced quality of life [6, 7]. Pain related to ARP/CP is hypothesized to have a multifactorial 
etiology with evidence of a strong central component of pain [8]. Traditionally, pain in pediatric 
CP has been treated through medical procedures, surgery, and opioids, but unfortunately. 
medical therapies have demonstrated limited efficacy for reducing pain [9].  
Surprisingly limited attention has been directed toward evaluating the efficacy of non-
pharmacological pain interventions for children with ARP/CP, as reflected by the absence of 
published RCTs. Psychological intervention for pain may be a particularly promising treatment 
avenue for this population, as it addresses psychosocial issues (e.g., negative mood, sleep 
problems) that are associated with centralized pain. In other populations of youth with chronic 
abdominal pain, psychological interventions using cognitive-behavioral therapy (CBT) have 
demonstrated efficacy in reducing pain symptoms, pain-related disability and emotional distress 
[10]. Moreover, delivering psychological interventions during childhood may present a unique 
opportunity to teach patients lifelong self-management skills and preemptively reduce the 
enormous impact of chronic pain, disability, and opioid dependency in adulthood as youth grow 
older [10, 11].  
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We are delivering CBT via the Internet to overcome the primary barriers that prevent 
children from receiving psychological intervention (i.e., geographic distance from treatment 
centers and the limited availability of psychological expertise) thus increasing accessibility [11]. 
Our research team has made significant progress in the development and evaluation of a web-
based CBT intervention for chronic pain, Web-based Management of Adolescent Pain 
(WebMAP), which has shown improvements in pain and disability outcomes comparable to 
conventional office-based CBT in youth with a variety of chronic pain conditions, including 
abdominal pain [12]. Following cognitive-behavioral, family systems, and social learning 
frameworks, the WebMAP program includes separate interventions for adolescents and their 
parents which target maladaptive cognitions and negative mood, problems with sleep, behavioral 
activation, and interpersonal behaviors. In this study, we adapted and tailored the WebMAP 
program for children and adolescents with pain related to ARP/CP.  
Moreover, identification of individual characteristics including psychosocial and genetic 
risk factors that increase or decrease treatment response can guide treatment-by-patient matching 
and advance the goal of personalized pain treatment in this population. Guiding the selection of 
treatment response moderators, developmental models of pediatric pain impact have identified 
child emotional factors (depression and anxiety) and family factors (family functioning) as 
strong predictors of chronic pain and pain-related disability in children [13, 14]. However, it not 
known whether these psychosocial factors predict better (or worse) response to treatment in 
pediatric ARP/CP. Additionally, while smoking and alcohol consumption are the major risk 
factors for CP in adults, genetic risk variants are strongly associated with ARP/CP in children 
and genetic testing is an integral part of evaluation. Thus, children comprise an excellent group 
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to evaluate whether (and which) genetic factors, in combination with psychosocial 
characteristics, may predict response to CBT pain treatment.  
Here we report the methodology of the first RCT of a psychological intervention to treat 
pain in pediatric ARP/CP. The primary goal of this randomized, single-blinded, placebo-
controlled trial is to determine the efficacy of web-based CBT (WebMAP) compared to web-
based education (WebED) in the largest cohort of well-phenotyped children with ARP/CP 
(INSPPIRE: INternational Study Group of Pediatric Pancreatitis: In search for a cuRE) [15]. Our 
secondary aims are to identify treatment response moderators; specifically, we will evaluate 
individual-level genetic and psychosocial characteristics associated with better (or worse) 
treatment response to WebMAP.  
Methods 
Participants and setting 
The clinical trial is registered and available at Clinicaltrials.gov (NCT03707431).  
The study sample will include 260 children and adolescents ages 10-18 years with ARP or CP 
and one of their parents (or caregivers). Eligible participants will have received a diagnosis of 
ARP or CP from one of 21 centers participating in the INSPPIRE 2 Cohort study [15]. See Table 
1 for a complete list of study eligibility criteria. Eligibility criteria are based on the INSPPIRE 2 
definition of ARP and CP [15] and a pain frequency that allows for delivery of a relevant 
treatment to youth experiencing frequent pain as well as detection of improvement within the 
study period. All 21 centers have been invited to participate and to date 16 centers have approval 
to refer participants to the study.  
Recruitment and enrollment.  
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Providers at participating INSPPIRE 2 sites will approach eligible children and families 
and provide them with a study flyer. If the family is interested and willing to participate, the 
provider will securely send their contact information to study staff via REDCap (Research 
Electronic Data Capture, Vanderbilt University) [16], email, fax, phone call, or voice message. 
Study staff will contact families within one business day of receiving the referral to assess 
eligibility and interest. At some participating sites as directed by their local Institutional Review 
Board (IRB), interested families will instead contact study staff directly after receiving the study 
flyer using a toll-free number or email address. Study staff blinded to the randomization schedule 
will obtain parent consent and child assent for study participation via electronic signature. Study 
staff will interact with participants weekly throughout the study and document missed time 
points and dropouts in a local tracking database. Reasons for withdrawal will be documented. 
Trial design and randomization.  
This study will utilize a single-blinded, randomized parallel group design. Assessments 
will be completed through the secure, web-based application REDCap [16] at baseline before 
randomization, immediately after the 8- to 12-week WebMAP intervention, and 6 months after 
intervention completion. The 6-month follow-up assessment will provide data on durability of 
treatment effects. Children and parents will complete their surveys independently. After 
completing the pre-treatment assessment, participants will be randomized to treatment condition: 
Group A, internet-delivered CBT (WebMAP) or Group B, internet-delivered pain education 
(WebED). Figure 1 summarizes the study design.  
Randomization will be implemented using a computer-generated randomization schedule 
to derive a group assignment for each ID number. Randomization will be blocked in sets of four. 
The randomization schedule will be stored in a password-protected Excel spreadsheet. To ensure 
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that study staff who perform the intervention assignment are blinded to the randomized 
allocation sequences, each participant’s group assignment will be revealed only after the 
participant completes the pre-treatment assessment. Participants will not be informed whether 
they are receiving an active or control treatment, however, they may be able to determine which 
group they are in based on the contents of the web program. All outcome measures will be 
completed online by study participants, further reducing the risk of bias.  
Intervention procedures. 
Patients assigned to the experimental arm of the study will receive access to the 
WebMAP program as previously described, [12] receiving internet-delivered CBT over an 8-12-
week intervention period. The control group will receive access to a pain education control web 
site for the same length of time (WebED). Both are password-protected web programs with 
separate child and parent versions. All study-related interventions will be adjunctive to patient 
care provided by their primary pediatric gastroenterologist. Although the treatment interventions 
are self-guided, study staff will have frequent interactions with participants (1-2 times weekly) 
during the treatment period for the purposes of monitoring program completion and for 
communicating with participants to evaluate any unwanted treatment reactions or adverse events. 
Internet cognitive-behavioral therapy condition (WebMAP). The program design and 
treatment content of WebMAP follow cognitive-behavioral, social learning, and family systems’ 
frameworks. This interactive, travel-themed program teaches relaxation skills, pain coping 
strategies, parent behavioral techniques, and parent communication methods. Because the 
original program was developed for children with a range of chronic pain conditions, we made 
several adaptations to tailor the program for pediatric ARP/CP. Based on qualitative feedback 
from children with ARP/CP and their parents, we integrated several patient video and vignette 
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examples of the impact of pain and application of skills for children with ARP/CP and their 
families. We also adapted the first educational module of WebMAP to focus specifically on pain 
related to pancreatitis. 
The eight child treatment modules include: 1) education about pancreatitis related pain, 
2) recognizing stress and negative emotions, 3) relaxation strategies (e.g., imagery, deep
breathing, progressive muscle relaxation), 4) implementing coping skills at school, 5) cognitive 
skills (e.g., recognizing and reducing negative thoughts), 6) lifestyle interventions (e.g., sleep 
habits, diet), 7) staying active (e.g., activity pacing), and 8) relapse prevention.  
The eight parent treatment modules are: 1) education about pancreatitis related pain, 2) 
recognizing stress and negative emotions, 3) behavioral strategies to increase their teen’s positive 
coping (e.g., attention and praise), 4) implementing strategies to support school goals, 5) 
modeling positive coping strategies, 6) sleep and lifestyle interventions, 7) family 
communication, and 8) relapse prevention. Each parent and child module takes approximately 20 
minutes to complete.  
The WebMAP program includes vignettes, videos of children with ARP/CP and their 
parents, illustrations, and reinforcing activities used throughout the program to increase 
interactivity. Children and parents identify personal goals and enter information, allowing for 
personalization of information for weekly behavioral assignments. Analogous to in-office CBT, 
children and parents are asked to complete 1 module per week and spend time practicing 
skills/completing assignments in 6 of the 8 modules. The following general structure is used in 
each module: summary of skills and educational material to be learned, rationale for why this 
information is important, main content, interactive quizzes (in game format with feedback), and 
an assignment screen presenting information for carrying out a specific skill over the coming 
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week. Completion of quizzes and assignments allow investigators to understand knowledge 
acquisition and retention of treatment content.  
Assignment completion. As in in-office CBT, assignments focus on practice and 
acquisition of skills taught within each weekly teen and parent module. For each assignment, 
participants are asked to report on the frequency of use, level of ease, and helpfulness of each 
skill. Participants are then provided with personalized feedback based on these responses. 
Personalized feedback includes a summary of progress, feedback on skills practice, strategies to 
overcome barriers to using skills, and encouragement to continue to use the program. 
Assignment completion is a requisite before teens and parents proceed to the subsequent module. 
Internet pain education condition (WebED).  The education control condition serves as 
an attention control condition to equalize time, attention, and computer usage by providing 
relevant information about chronic pain. The program contains 8 modules with information 
compiled from publicly available educational websites about chronic pain (e.g., WebMD, 
AboutKidsHealth, National Pancreas Foundation). We developed additional educational content 
about pain and symptoms in ARP/CP to be relevant and credible for these children and their 
parents. The control version does not include any instruction on the behavioral and cognitive 
skills taught within the WebMAP program. Children and parents are instructed to log in and read 
one education module per week for approximately 20 minutes (the same interval as the CBT 
group). In our prior RCTs that have used a pain education control website, parents and children 
have shown a high level of engagement and high ratings of treatment credibility [12].  
Treatment fidelity. The administrative interface of the web program has a tracking 
system in place for recording each time a user logs in or completes a module, allowing 
measurement of web site usage. All completed data fields within modules are stored (e.g., 
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completion of quizzes, assignments), generating a comprehensive activity record of each 
individual’s program usage and their acquisition of skills and knowledge within the program. 
Measures. 
Covariates. Participant demographic information (age, sex, race, ethnicity, income, 
occupation, marital status) will be collected via parent report at baseline. 
Treatment expectancies. After randomization, youth and their parents will complete a 
baseline measure of treatment expectancies [17]. This 10-item questionnaire asks youth and their 
parents to rate the likelihood that Internet pain treatment will lead to symptom improvement on 
5-point rating scales (0 = not at all likely, 4 = extremely likely). Higher scores on this measure
indicate more positive treatment expectancies. 
Primary outcome: Abdominal pain. The Abdominal Pain Index (API) will be used to 
measure abdominal pain severity at all three time points. The API yields a composite score for 
pain severity derived from child- and parent-report on pain frequency, duration, and intensity 
over the prior two weeks. The API is a validated measure of abdominal pain severity that 
contains four (parent version) or five items (child version) [18].  
Secondary outcomes. 
Pain-related disability. Child report on the Child Activity Limitations Interview (CALI-
9), diary version will be used to assess pain-related disability at each time point. The CALI-9 is a 
validated instrument that assesses perceived difficulty in completing standard daily physical, 
social, and recreational activities due to pain [19]. Each of the 9 items is scored on a 6-point 
scale, with higher scores indicating greater pain-related disability. Children complete the diary 
daily for 7 days at each of the three time points. 
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Anxiety and depression. Child report on the PROMIS Pediatric Emotional Distress Scales 
will be used to assess symptoms of anxiety and depression at all three time points. The PROMIS 
Pediatric Emotional Distress Scales is a validated instrument that includes an 8-item scale of 
anxiety symptoms (fear, worry, hyperarousal) and an 8-item scale of depressive symptoms [20]. 
Raw scores from each scale are converted to T-scores, with a distribution mean of 50 (SD ± 10).  
Self-efficacy. The Child Self-Efficacy Scale will be used to assess child participants’ 
perceived ability to complete various activities while they are in pain (e.g., How sure are you 
that you can make it through a day of school with pain?) [21]. Each item is scored on a 5-point 
scale, with higher numbers indicating lower self-efficacy (i.e., 1 = very sure to 5 = very unsure). 
Pain interference. Child report on the PROMIS Pain Interference Scale will be used to 
assess how much pain hinders participation in various social, recreational, cognitive, and 
physical activities [22]. This scale consists of 8 items, each item scored on a 5-point scale. 
Higher ratings indicate greater pain-related interference.  
Parent impact. Parent report on the Bath Adolescent Pain – Parental Impact 
Questionnaire (BAP-PIQ) will be used to assess family functioning and emotional impact 
associated with parenting a child with chronic pain [23]. Each item on the BAP-PIQ is scored on 
a 5-point scale with higher scores indicating greater impairment.  
Health-related quality of life. The Pediatric Quality of Life Inventory (PedsQL) will be 
used to assess health-related quality of life (HRQOL) via child and parent report at all three time 
points [24]. Each of the 23 items is scored on a 5-point scale. Higher scores indicate better 
physical, emotional, social, and school functioning.  
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Health care use. The Client Service Receipt Inventory (CSRI) [25] will be used to assess 
health care use at baseline and 6 month follow up. The CSRI has been adapted for adolescents 
with chronic pain  [26] and subsequently used in pediatric pain populations [27]. In this survey, 
parents report on all health service use (e.g., hospitalizations, outpatient health care visits) 
including medication usage (including opioid and non-opioid medications) during the previous 9 
months.   
Treatment satisfaction. The Treatment Evaluation Inventory [25] – Short Form (TEI) will 
be used to assess treatment satisfaction via child and parent report at post-treatment and follow-
up [28]. The TEI assesses acceptability and satisfaction with a treatment program. 
Treatment experiences. Any unwanted experiences during treatment will be collected at 
post-treatment and follow-up using child and parent report on a self-report scale developed for 
this study that asks participants about any negative changes in stress, anxiety, or pain symptoms 
due to study participation.   
Predictors/Moderators. 
Clinical and genetic variables. We will include baseline information collected from the 
INSPPIRE 2 study, including clinician report of history and symptoms, and a blood draw for 
testing subjects’ ARP/CP genetic variants. We will analyze 79 complete genes and 141 
additional targets. Genetic susceptibility is the major driving factor for the onset of ARP/CP in 
children and genetic testing is an integral part of the evaluation.  Consequently, our genetic 
screen will cover Mendelian disorders of the exocrine pancreas including: cystic fibrosis, CFTR-
related disorders, Shwachman-Diamond syndrome, Johanson-Blizzard syndrome, hereditary 
pancreatitis, and Maturity-onset diabetes of the young (CEL, MODY8). See Table 3 for a list of 
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genetic variables. Each of these genetic variants has the potential to influence development of 
pain, the pattern of pain, and the response to therapy. 
Baseline demographic and psychosocial variables. We will test several possible baseline 
demographic and individual child moderators that may have an impact on the intervention effect. 
This will include child age and sex, and psychosocial variables (i.e.,  baseline anxiety and 
depression on the PROMIS Pediatric Emotional Distress Scales [20]. 
Sample Size and Power Calculations  
We based power calculations on expected differences in the primary outcome (API) 
derived from our previous trials of WebMAP.  The estimate of the standard deviation of API is 
approximately 0.85. We expect a difference of 0.30 between WebMAP and WebED in the mean 
score of abdominal pain severity at 6-month follow-up, corresponding to a small effect size 
(Cohen’s d approximately = .30 - .35). At the significance level of 0.05, a sample size of 115 
subjects per group is required to have 80% power to detect this difference. Taking into account 
10-15% attrition, we will therefore plan to enroll 130 patients per group.  The power calculation
for the secondary aim is based on correlation coefficient. Given the sample size of 115 subjects 
in the treatment group, we have 80% power to detect the correlation of 0.27 between gene (or 
baseline clinical characteristics) and API, at the significance level of 0.05. As the LMM is more 
efficient and is an intent-to-treat approach that will use data from the full sample, the actual 
power will be greater.  
Data Analysis 
Distributions of primary and secondary outcome variables at each time point (and on 
difference scores between time points) will be examined first with summary statistics and 
graphical tools. For outcome variables with highly skewed distributions, we will either apply 
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transformation or non-parametric test procedures. Preliminary work will also involve 
computation of scale reliabilities (e.g., internal consistency using Cronbach’s alpha) of all self-
report measures. The analysis will be an intent-to-treat analysis including all randomized 
subjects.  
Analytic Plan: Treatment efficacy.  LMM and GLMM will be used to compare the 
change in the primary and secondary outcomes over time (from baseline to follow-ups) between 
WebMAP and WebED. These models will include time, treatment condition (1 = CBT condition; 
0 = Education condition), and their interaction (i.e., time X treatment condition). We will include 
demographic and clinical factors as needed to adjust for potential confounding effects. For 
categorical variables, the generalized linear mixed model (GLMM) will be used to compare the 
changes over time (from baseline to follow-ups) between WebMAP and WebEd.  
Analytic Plan: Moderators of treatment response. Linear mixed models (LMM) will 
be used to evaluate individual genetic, clinical, (e.g., demographics, age at diagnosis, ARP or CP 
diagnosis, number of pancreatitis attacks) and psychosocial characteristics (e.g., child anxiety, 
child depression, and family functioning) as general predictors and moderators of treatment 
response. Repeated measures of abdominal pain severity and health-related quality of life in the 
CBT group will serve as the outcome variables. These models will comprise the following 
variables: (1) intercept and Time (i.e., the slope terms); (2) individual characteristics that were 
used to predict the intercept (pre-treatment score) and slopes of improvement (i.e., individual 
characteristic X time) and (3) potential predictor/moderator variables, treatment condition, and 
their interaction (i.e., individual characteristic X treatment X time).  
Following the data analytic approach advocated by Kraemer et al [29], individual 
characteristics will be considered moderators if they predict a better (or worse) response to the 
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treatment condition compared to the control condition. Moderator variables will require evidence 
of a significant interaction between the predictor (individual characteristic), study treatment 
condition (dichotomized: 0 = Internet CBT; 1 = Internet Education), and time (i.e., individual 
characteristic X treatment X time). Thus, a significant predictor X treatment X time interaction 
indicates that the trajectory of treatment response differs across the treatment conditions and 
depends on the level of the moderator variable. On the other hand, general predictors are 
individual characteristics associated with treatment outcome irrespective of study condition (i.e., 
across both conditions); thus there is evidence of a significant interaction with time point (i.e., 
Individual characteristic X Time) but no significant interaction with treatment condition.  
To investigate multiple genetic, clinical, and psychosocial individual characteristics as 
moderators, we will first conduct univariate analysis by independently testing the effects of each 
individual characteristic on the abdominal pain severity outcome to see if there is reasonable 
signal of whether they will have a significant effect on the rate of symptomatic improvement 
using a p-value threshold of <.10. Using this procedure, only those individual characteristics that 
had a significant interaction with time at the p-value < .10 level in univariate analysis will be 
included in a final multivariate model. If the number of putative general predictors/moderators 
included in the final multivariate model is still large, model selection (e.g., using LASSO) will 
be performed to obtain a parsimonious model that could identify characteristics that significantly 
moderate treatment outcomes. Further analysis utilizing machine learning programs for cluster 
analysis, such as principle component analysis, will be conducted as complementary and 
confirmatory analyses. 
  For models testing genetic polymorphisms that predict treatment response, in the initial 
evaluation, “genetic signatures” will be used as covariates. This approach markedly reduces 
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complexity by combining known pathogenic variants in a class into an object such as “CFTR-
related disorders”, “Pathologic Trypsins”, “Unfolded protein response (UPR)”, “Lipotoxicity”, 
“idiopathic” and “others” for etiology, as well as “opiate pharmacogenetics defect”, “pain 
receptor” and others for modifiers. In addition, pathogenic variants with large effects (e.g. 
PRSS1 p.R122H, SPINK1 p.N34S) or high frequency (e.g. CTRC g.60G haplotype) will be 
evaluated as independent moderators (i.e., will only be evaluated in univariate analyses and not 
in a final multivariate model).  
Discussion 
Abdominal pain is highly prevalent in children with ARP and CP [7] and is associated 
with negative impact on multiple domains of physical, psychological, and social functioning[7, 
30]. Given that the burden of pain worsens with age, early implementation of therapies during 
childhood are critically important for reducing opioid dependency and preventing functional 
impairments that develop with advanced disease in adulthood [31]. Currently, effective non-
pharmacological pain interventions do not exist for pediatric ARP/CP. In this paper, we report 
the methodology of the first NIH-funded randomized multicenter clinical trial to test the efficacy 
of an internet-delivered psychological intervention in a large pediatric ARP/CP cohort.  
The results of this trial will have important implications for pain management in children 
with ARP/CP and their families by understanding whether a psychological self-management 
approach to chronic pain symptoms can reduce pain and improve quality of life. This study 
represents a significant advance in pediatric pancreatology as it is the first to introduce a 
psychological pain management option for this population, that may represent a new model of 
treatment in ARP/CP.  This trial will also examine whether any genetic, clinical, and 
psychosocial characteristics predict or moderate treatment response, further expanding our 
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understanding of this disease and enabling precision medicine approaches. Specifically, we will 
be able to identify whether patient-specific clinical and psychosocial factors are associated with 
improved response to web-based CBT. In addition, our internet-delivered program is a cost-
effective alternative to in-office CBT that may increase accessibility and diminish 
socioeconomic or geographic disparities in care.  
In summary, the results of this trial are expected to provide information on the main and 
moderating effects of a web-based psychological pain management program for pediatric 
ARP/CP. If successful, the intervention has potential for widespread dissemination to children 
with ARP/CP at treatment centers around the world.   
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Figure 1. CONSORT diagram depicting participant flow.] 
Group A: Allocated to WebMAP intervention 
(8-12 weeks) 
Child 
 CBT module (one per week)
Parent
 CBT module (one per week)
Group B: Allocated to WebED attention control 
(8-12 weeks) 
Child 
 Pain Education module (one per week)
Parent
 Pain Education module (one per week)
Assessed for eligibility 
Allocation
Follow-Up 








Table 1. Study eligibility criteria 
Inclusion Criteria 
 Child diagnosed with chronic or acute recurring pancreatitis
 Child age is between 10-18 years
 Child abdominal pain frequency > once/month for at least 3 months
 Child and parent have access to the Internet on any web-enabled device
Exclusion Criteria 
 Child or parent is unable to read/write or speak English
 Child is unable to read at the 5th grade level due to learning or developmental delays
 Child has cystic fibrosis
 Child has Shwachman-Bodian-Diamond Syndrome
 Child diagnosed with acute pancreatitis with no evidence of chronic or persistent
abdominal pain
 Child has anticipated surgery (TPIAT or other) during study participation (6-month
time frame)
 Child had recent surgery (TPIAT or other) within the past thirty days (or longer if still
in acute recovery period)
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Table 2. Study measures 
Measure Description of measure Respondent Time point 
administered 
T1 T2 T3 
Demographic and clinical measures 
Background 
Questionnaire 
Obtain demographic and socioeconomic 
information including age, sex, gender, race, 
ethnicity, family income, occupation, and 




Rate expectations that the program will be 
useful and helpful. 
Child, Parent ✔
Primary outcome measures 
Abdominal Pain 
Index (API) 
Assess abdominal pain intensity, duration, 
and frequency during the previous 2 weeks. 
Child, Parent ✔ ✔ ✔ 





9-item measure used to assess daily pain-
related disability related to limitations in
common activities for 7 days in a pain diary.





Includes 8-item scale of anxiety (fear, worry, 
hyperarousal) and 8-item scale of depressive 
symptoms.  
Child ✔ ✔ ✔
Child Self-
Efficacy Scale 
7-item measure used to assess perceived
ability to complete certain activities when in
pain.






8-item measure used to quantify the degree
to which pain restricts engagement in various
activities.





Assess parent perception of burden, family 
functioning, and emotional distress related to 
caring for an adolescent with pain.  
Parent ✔ ✔ ✔
Pediatric Quality 
of Life Inventory 
Assess physical, emotional, social, and 
scholastic functioning via child self-report 
and parent-proxy report.  
Child, Parent ✔ ✔ ✔ 
Health Care Use 
Survey 
Report use of various health care services 
such as clinic visits, emergency visits, and 
opioid and non-opioid medications, as well 
as health-related impacts during the previous 
9 months. 
Parent ✔ ✔ 
Treatment 
Evaluation 
Inventory – Short 
Form 
Assess treatment satisfaction and 
acceptability   




Report unwanted effects of study 
participation on stress, anxiety, and pain 
symptoms.  






Includes clinician report of pancreatitis 
treatment history, and blood draw for testing 






Table 3. Genetic variables 
Primary ARP/CP susceptibility genes: Description 
CASR Calcium-sensing Receptor 
CFTR Cystic Fibrosis Transmembrane Conductance Regulator 
SBDS Shwachman-Bodian-Diamond Syndrome Ribosome 
Maturation Factor 
SBDSP Shwachman-Bodian-Diamond Syndrome Pseudogene 
SPINK1 Serine Peptidase Inhibitor, Kazal Type 1 
CEL Carboxyl Ester Lipase 
CELP Carboxyl Ester Lipase Pseudogene 
CPA1 Carboxypeptidase A1 
CLDN1 – key SNPs Claudin 1 (key single nucleotide polymorphisms) 
PRSS1 Serine Protease 1 
PRSS2 Serine Protease 2 
PRSS3 Serine Protease 3 
PRSS1-2 locus Serine Protease 1-2 locus 
GGT1 Gamma-Glutamyltransferase 1 
Lipid metabolizing genes associated with 
hypertriglyceridemia and ARP:  
APOA5 Apolipoprotein A5 
APOC2 Apolipoprotein C2 
FABP Fatty Acid Binding Protein 
LPL Lipoprotein Lipase 
Inflammation severity variants: 
IL10 Interleukin 10 
IL22 Interleukin 222 
IL22RA1 Interleukin 22 Receptor Subunit Alpha 1 
IL22RA2 Interleukin 22 Receptor Subunit Alpha 2 
IL23R Interleukin 23 Receptor 
Drug metabolism and pain management genes: 
COMT Catechol-O-Methyltransferase 
HTR2A 5-Hydroxytryptamine Receptor 2A
CYP2C19 Cytochrome P450 Family 2 Subfamily C Member 19 
CYP2D6 Cytochrome P450 Family 2 Subfamily D Member 6 
CYP3A4 Cytochrome P450 Family 3 Subfamily A Member 4 
CYP3A5 Cytochrome P450 Family 3 Subfamily A Member 5 
OPRD1 Opioid Receptor Delta 1 
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